Every Form 4 that NewGenIvf Group Limited (NIVF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NIVF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NIVF filings page.
NewGenIvf Group Ltd (NIVF) director and ten percent owner Cheung Kong Yiu reported a series of acquisitions of Class A ordinary shares. In four tranches issued under share purchase agreements, he acquired a total of 3,722,223 Class A ordinary shares, with reported prices per share ranging from $1.00 to $1.50. The filing states that the first three tranches reflect adjustments for a 1-for-3 reverse stock split, covering 222,223 shares on May 28, 2026, 500,000 shares on June 2, 2026, 500,000 shares on June 18, 2026, and 2,500,000 shares on July 27, 2026, all issued directly to the reporting person under share purchase agreements between him and the company.
NewGenIvf Group Ltd (NIVF) reported that Chief Marketing Officer Fong Hei Yue Tina received a grant of 272,140 stock options to acquire Class B Ordinary Shares at an exercise price of US$0.0001 per share. The options vest upon grant and expire on August 17, 2033, granted under the company’s 2024 Share Incentive Plan and an Employee Stock Option Agreement dated August 17, 2026. Following this award, the reporting person holds 345,787 stock options in total.
NewGenIvf Group Ltd (NIVF) granted its Chairman & CEO, Siu Wing Fung Alfred, stock options for 272,140 Class B Ordinary Shares. The options have an exercise price of US$0.0001 per share, vest immediately upon grant, and expire on August 17, 2033. Following this award, the reporting person holds 345,787 stock options directly. The grant was made under the company’s 2024 Share Incentive Plan and an Employee Stock Option Agreement dated August 17, 2026.
NewGenIvf Group Ltd director Siu Wing Fung Alfred received a grant of 73,647 Employee Share Options as part of his compensation. These options have an exercise price of $0.0001 per Class B ordinary share and expire on July 8, 2033.
The options were granted under the company’s 2024 Share Incentive Plan and an option agreement dated July 8, 2026. They vest over 36 months, with 10% vesting on August 8, 2026 and the remainder vesting in approximately 2.6% monthly tranches, aligning incentives over a multi-year period.
NewGenIvf Group Ltd director receives a new equity award. Director Fong Hei Yue Tina was granted employee share options covering 73,647 Class B ordinary shares at an exercise price of $0.0001 per share.
The options were granted under the 2024 Share Incentive Plan and vest over 36 months, with 10% vesting on August 8, 2026 and the remaining options vesting in roughly 2.6% monthly tranches. Following this grant, the filing shows 73,647 options held directly.
HRT FINANCIAL LP, a ten percent owner of NewGenIvf Group Ltd, reported an open-market sale of Common Stock. On June 4, 2026, it sold 64,945 shares at $0.781 per share. After this transaction, HRT FINANCIAL LP directly holds 18,134 shares of NewGenIvf common stock.
NewGenIvf Group director Siu Wing Fung Alfred exercised vested stock options to acquire 56,851 Class B Ordinary Shares at $0.0001 per share on June 4, 2026. The exercise, under the 2024 Share Incentive Plan and an employee option agreement, raised his direct holdings to 56,881 shares after the transaction.
NewGenIvf Group Ltd director Fong Hei Yue Tina exercised stock options to acquire additional shares in the company. She exercised vested options to receive 56,851 Class B Ordinary Shares at an exercise price of $0.0001 per share under the issuer's 2024 Share Incentive Plan.
Following this option exercise, she directly holds 56,890 Class B Ordinary Shares. The options were granted under an employee share option agreement dated 4 May 2026, were accelerated by the independent directors on 26 May 2026, and were exercised on 4 June 2026. This is a compensation-related derivative exercise, not an open-market purchase or sale.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On June 2, it bought 23,018 shares at an average price of $0.944 per share. On June 3, it bought an additional 11,738 shares at an average price of $0.875 per share. After these transactions, HRT Financial LP directly holds 83,079 shares of NewGenIvf common stock.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported an open-market sale of 85,317 shares of Common Stock at $0.80 per share on May 27, 2026. After this transaction, HRT Financial LP directly holds 54,561 shares of NewGenIvf Common Stock.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On May 22, 2026 and May 26, 2026, it bought a combined 165,534 shares at prices of $0.99 and $0.92 per share. Following these transactions, HRT Financial LP directly holds 139,878 shares of NewGenIvf Group Ltd common stock.
NewGenIvf Group Ltd Chairman & CEO Siu Wing Fung Alfred received a grant of stock options to acquire 56,851 Class B Ordinary Shares at an exercise price of US$0.0001 per share under the company’s 2024 Share Incentive Plan.
The options vest monthly from 4 June 2026 through 4 May 2029, starting with 5,685 options and then 1,462 options on most monthly vesting dates, with 1,458 options vesting in the final tranche. The options expire on 4 May 2033, and following this grant he holds 56,881 stock options directly.
NewGenIvf Group Ltd reported that Chief Marketing Officer Fong Hei Yue Tina received a grant of stock options to acquire 56,851 Class B Ordinary Shares. The options carry an exercise price of US$0.0001 per share and were granted under the company’s 2024 Share Incentive Plan.
The award vests over time: 5,685 options on June 4, 2026, 1,462 options on the 4th day of each month from July 4, 2026 through April 4, 2029, and 1,458 options on May 4, 2029. The options expire on May 4, 2033, and following this grant she holds 56,890 options directly.